Fortfahren mit
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
| Ihnen/SKU | Verfügbarkeit | Preis |
|---|---|---|
1 kit | Warenkorb auf Verfügbarkeit prüfen | CHF 902.00 |
Über diesen Artikel
NACRES:
NA.84
UNSPSC Code:
12352200
CHF 902.00
Warenkorb auf Verfügbarkeit prüfen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenGeneral description
designed to simplify the identification and characterization of SARS-CoV-2 inhibitors.
Application
The SARS-CoV-2 Inhibitors Screening Kit is a convenient tool, designed to simplify the identification and characterization of SARS-CoV-2 inhibitors.The crutial interaction between the SARS-CoV-2 and human cells accrues through the protein-protein interaction of human receptor ACE2 and viral protein Spike – S protein. The receptor binding domain (RBD) of S protein is the domain that specifically binds to ACE2. Our SARS-CoV-2 Inhibitors Screening Kit includes both human ACE protein and viral RBD of S protein. The kit is based on a colorimetric ELISA, where biotinylated ACE2 (ACE2-biotin) and Extravidin®-peroxidase are used to detect the ACE2:RBD interaction. One molecule of Extravidin® binds four molecules of biotin by a non-covalent interaction that is essentially irreversible. Binding visualization is achieved by using o-Phenylenediamine dihydrochloride (OPD), a peroxidase substrate with absorbance at 450 nm.
Inhibitors and neutralizing antibodies against RBD that interfere with the ACE2:RBD interaction will result in reduced colorimetric signal.
Inhibitors and neutralizing antibodies against RBD that interfere with the ACE2:RBD interaction will result in reduced colorimetric signal.
Biochem/physiol Actions
SARS-CoV-2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to Coronaviridae (CoVs) - a large family of viruses that usually cause mild to moderate upper-respiratory tract diseases.1 CoVs are single-stranded RNA viruses. They have a high mutation rate and are therefore highly diverse.1 Their hosts include human and non-human mammals, as well as birds.1
SARS-CoV-2 infects cells which express angiotensin converting enzyme 2 (ACE2).2 ACE2 binds to the viral envelope-associated spike (S) protein as a cellular receptor, following proteolytic cleavage of both S and ACE2 by serine proteases.3 S protein is believed to be the target of neutralizing antibodies because it is the main trans-membrane glycoprotein responsible for receptor-binding and virion entry.4
The S protein is a trimeric protein. During the binding to ACE2, S protein undergoes a substantial structural rearrangement to facilitate the fusion of the viral membrane with the host cell membrane.5 The receptor binding domain (RBD) of S protein is the domain that specifically binds to ACE2. RBD is the major target for neutralizing antibodies for coronaviruses6, and anti-RBD antibodies likely correlate with virus neutralization.7
SARS-CoV-2 infects cells which express angiotensin converting enzyme 2 (ACE2).2 ACE2 binds to the viral envelope-associated spike (S) protein as a cellular receptor, following proteolytic cleavage of both S and ACE2 by serine proteases.3 S protein is believed to be the target of neutralizing antibodies because it is the main trans-membrane glycoprotein responsible for receptor-binding and virion entry.4
The S protein is a trimeric protein. During the binding to ACE2, S protein undergoes a substantial structural rearrangement to facilitate the fusion of the viral membrane with the host cell membrane.5 The receptor binding domain (RBD) of S protein is the domain that specifically binds to ACE2. RBD is the major target for neutralizing antibodies for coronaviruses6, and anti-RBD antibodies likely correlate with virus neutralization.7
Features and Benefits
Our SARS-CoV-2 Inhibitors Screening Kit will support your research, enabling to screen and discover inhibitors as potential drugs for COVID-19
Supportive calculator (Click here to download a calculator excel file)
Legal Information
ExtrAvidin is a registered trademark of Merck KGaA, Darmstadt, Germany
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| description Based on SPIKE - ACE2 Binding Assay, Colorimetric, sufficient for 200 tests | description ≥95% (HPLC), lyophilized powder | description Spike protein RBD recombinant, expressed in HEK 293 cells | description ≥95% (HPLC), lyophilized powder |
| shipped in ambient | shipped in - | shipped in ambient | shipped in - |
| Quality Level 200 | Quality Level 300 | Quality Level 300 | Quality Level 300 |
| storage temp. 2-8°C | storage temp. −20°C | storage temp. −20°C | storage temp. −20°C |
signalword
Danger
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 2 - Carc. 2 - Eye Dam. 1 - Muta. 2 - Skin Sens. 1 - STOT SE 3
target_organs
Respiratory system
Lagerklasse
10 - Combustible liquids
wgk
WGK 3
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.







